STOCK TITAN

Cybin Inc Stock Price, News & Analysis

CYBN NYSE

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.

Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.

Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.

Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.

Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) has expanded its clinical team to support the upcoming Phase 3 pivotal program for CYB003 in Major Depressive Disorder (MDD). Key appointments include:

- Dr. Mirza Rahman as Senior VP, Patient Safety & Pharmacovigilance
- Dr. Marcelo Gutierrez as VP, Clinical Pharmacology
- Dr. Atul R. Mahableshwarkar as program lead for CYB003
- Dr. Tom Macek as program lead for CYB004

The strengthened team will support CYB003 pivotal trials, consisting of three studies spanning up to 12 countries. These additions bring expertise in patient safety, pharmacovigilance, clinical pharmacology, and drug development, important for advancing Cybin's proprietary deuterated psilocin program for adjunctive treatment of MDD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event will take place on September 26, 2024.

Amir Inamdar, Cybin's Chief Medical Officer, will be part of a panel discussion titled 'Advancement in Psychedelic Therapies for Neuropsychiatry'. The panel will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET.

Interested parties can access the webcast through a provided link. An archived version of the webcast will also be available on Cybin's investor relations website under the Events & Presentations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
conferences
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, provided updates on its key clinical programs. The company is preparing to initiate a pivotal Phase 3 study for CYB003, its deuterated psilocin program for Major Depressive Disorder (MDD), which has received FDA Breakthrough Therapy Designation. Cybin expects to report 12-month efficacy data from the Phase 2 study of CYB003 in early Q4 2024.

For CYB004, Cybin's deuterated dimethyltryptamine program for Generalized Anxiety Disorder (GAD), the company anticipates Phase 2 topline efficacy and safety results by year-end 2024 or early Q1 2025. Cybin has also strengthened its R&D team with the addition of Dr. Atul R. Mahableshwarkar and Dr. Tom Macek as program leads for CYB003 and CYB004, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
none
Rhea-AI Summary

Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has completed a share consolidation on a 38:1 basis. The consolidation, effective immediately, reduces the company's outstanding common shares from 759,692,495 to approximately 19,991,907. Trading of the consolidated shares begins today. This move does not affect shareholders' ownership percentages or voting power, except for minor adjustments due to fractional shares. The company has also adjusted the exercise price and number of shares issuable for outstanding warrants and options in line with the consolidation ratio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4096.08%
Tags
none
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York, NY. CEO Doug Drysdale will engage in a fireside chat on Monday, September 9, 2024, at 8:30 a.m. ET, which will be webcast live and later archived on the company's investor relations website.

Additionally, Drysdale will join a panel discussion titled "Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders" on Tuesday, September 10, 2024, at 3:00 p.m. ET. This event highlights Cybin's commitment to developing innovative next-generation treatment options for mental healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Summary

Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) held its annual and special meeting of shareholders on August 27, 2024, with 59.66% of total issued and outstanding common shares represented. Key outcomes include:

1. Appointment of Zeifmans LLP as auditor
2. Election of seven directors
3. Approval of common share consolidation
4. Amendments to equity incentive plan, shareholder rights plan, and common share purchase warrants

The company announced a 38:1 share consolidation, reducing outstanding shares from 759,692,495 to approximately 19,991,907. This consolidation is expected to be effective around September 19, 2024, subject to CBOE Canada approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) has announced plans to initiate a Phase 3 pivotal trial of CYB003 for the adjunctive treatment of Major Depressive Disorder (MDD) in late summer 2024. This follows a successful Type B Initial Breakthrough Therapy Meeting with the FDA. The trial will include 30 clinical sites across the United States and Europe. Cybin's Phase 2 study showed promising results, with 75% of patients in remission from depression four months after two 16mg doses of CYB003. The company plans to implement measures to mitigate functional unblinding risks in the pivotal study, including a three-arm design and the use of remote, independent, blinded raters. Cybin expects to report 12-month efficacy data from the Phase 2 study in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) reported its Q1 FY2025 financial results and recent business highlights. Key points include:

- Phase 3 multinational study of CYB003 for Major Depressive Disorder (MDD) expected to begin in late summer 2024 across 30 clinical sites in the US and Europe

- 12-month efficacy results from Phase 2 study of CYB003 in MDD expected Q4 2024

- Additional US patent granted for the CYB004 program

- Strengthened R&D team with experienced drug development leaders

- Cash totaled C$183 million as of June 30, 2024

- Net loss was C$15 million for Q1 FY2025

- Cash-based operating expenses were C$16 million for Q1 FY2025

- Cash flows used in operating activities were C$27 million for Q1 FY2025

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, announces its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-14, 2024 in Boston, MA. Doug Drysdale, Cybin's CEO, will engage in a fireside chat on Tuesday, August 13, 2024, at 2:00 p.m. ET.

The fireside chat will be webcast live and accessible to the public. An archived version of the webcast will be available on Cybin's investor relations website under the Events & Presentations page. This participation highlights Cybin's commitment to developing innovative next-generation treatment options in mental healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Cybin Inc. (NYSE American: CYBN) has announced significant insider stock purchases, highlighting confidence in the company's direction. Senior officers and directors have collectively acquired substantial shares, reinforcing faith in Cybin's strategic advancements. The company has achieved notable milestones, including FDA Breakthrough Therapy Designation for CYB003 for major depressive disorder (MDD) and positive Phase 2 results, showing a 14-point MADRS score reduction. Cybin is set to launch a Phase 3 study for CYB003 and a Phase 2 study for CYB004 targeting generalized anxiety disorder (GAD). Financially, Cybin is robust, with C$209 million in cash reserves as of March 31, 2024, and a recent US$150 million private placement. Zacks Investment Research upgraded Cybin to a Zacks Rank #2 (Buy), citing a 52.6% improvement in earnings estimates for FY 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $7.47 as of May 23, 2025.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 137.9M.
Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Stock Data

137.93M
18.64M
238.24%
41.95%
5.19%
Biotechnology
Healthcare
Link
Canada
Toronto